Human IL-3 Recombinant Protein, PeproTech®

Product Details	
Size	100 µg
Species	Human
Published Species	Virus, Non-human primate, Hamster, Mouse, Human
Expression system	E. coli
Amino acid sequence	APMTQTTSLK TSWVNCSNMI DEIITHLKQP PLPLLDFNNL NGEDQDILME NNLRRPNLEA FNRAVKSLQN ASAIESILKN LLPCLPLATA APTRHPIHIK DGDWNEFRRK LTFYLKTLEN AQAQQTTLSL AIF
Molecular weight	15 kDa
Class	Recombinant
Type	Protein
Purity	98% by SDS-PAGE gel and HPLC analyses.
Endotoxin concentration	<1 EU/µg
Activity	The ED50 as determined by the dose-dependent stimulation of the proliferation of human TF-1 cells is 0.1 ng/ml, corresponding to a specific activity of 1 x 10^7 units/mg.
Conjugate	Unconjugated
Form	Lyophilized
Purification	purified
Contains	no preservative
Storage conditions	-20°C

Applications	Tested Dilution	Publications
Western Blot (WB)	Assay-dependent	-
ELISA (ELISA)	Assay-dependent	-
Neutralization (Neu)	-	1 Publication
Functional Assay (Functional)	Assay-dependent	-
In vitro Assay (IV)	-	374 Publications
Miscellaneous PubMed (Misc)	-	42 Publications

Product Specific Information

Recombinant Human IL-3 is a 15.0 kDa globular protein containing 133 amino acid residues.

This product is shipped at ambient temperature. For storage, handling and reconstitution information, please see the lot-specific Certificate of Analysis

Product Images For Human IL-3 Recombinant Protein, PeproTech®



Human IL-3 Protein (200-03-100UG) in Functional
Bioassay analysis of Human IL-3 Recombinant Protein, PeproTech® (Product # 200-03-1MG).



Human IL-3 Protein (200-03-100UG) in Functional
WHO Comparison of Human IL-3 Recombinant Protein, PeproTech® (Product # 200-03-1MG).

417 References

Neutralization (1)

Blood

Multidirectional interactions are bridging human NK cells with plasmacytoid and monocyte-derived dendritic cells during innate immune responses.

Authors: Della Chiesa M,Romagnani C,Thiel A,Moretta L,Moretta A

Year
2006

Species
Human

In vitro Assay (374)

Cell death & disease

Venetoclax triggers sublethal apoptotic signaling in venetoclax-resistant acute myeloid leukemia cells and induces vulnerability to PARP inhibition and azacitidine.

"200-03 was used in Cell Culture to identify a new vulnerability in acquired venetoclax-resistant AML cells and identify PARP inhibition as a potential therapeutic approach to overcome acquired venetoclax resistance in AML."

Authors: Tambe M,Unterberger S,Kriegbaum MC,Vänttinen I,Olgac EJ,Vähä-Koskela M,Kontro M,Wennerberg K, Heckman CA

Year
2024

Species
Human

Nature

Tuberculosis in otherwise healthy adults with inherited TNF deficiency.

"200-03 was used in Cell Culture to report two adults with recurrent pulmonary tuberculosis who are homozygous for a private loss-of-function TNF variant."

Authors: Arias AA,Neehus AL,Ogishi M,Meynier V,Krebs A,Lazarov T,Lee AM,Arango-Franco CA,Yang R,Orrego J, Corcini Berndt M,Rojas J,Li H,Rinchai D,Erazo-Borrás L,Han JE,Pillay B,Ponsin K,Chaldebas M,Philippot Q,Bohlen J, Rosain J,Le Voyer T,Janotte T,Amarajeeva K,Soudée C,Brollo M,Wiegmann K,Marquant Q,Seeleuthner Y,Lee D,Lainé C,Kloos D,Bailey R,Bastard P,Keating N,Rapaport F,Khan T,Moncada-Vélez M,Carmona MC,Obando C,Alvarez J, Cataño JC,Martínez-Rosado LL,Sanchez JP,Tejada-Giraldo M,L'Honneur AS,Agudelo ML,Perez-Zapata LJ,Arboleda DM,Alzate JF,Cabarcas F,Zuluaga A,Pelham SJ,Ensser A,Schmidt M,Velásquez-Lopera MM,Jouanguy E,Puel A, Krönke M,Ghirardello S,Borghesi A,Pahari S,Boisson B,Pittaluga S,Ma CS,Emile JF,Notarangelo LD,Tangye SG,Marr N,Lachmann N,Salvator H,Schlesinger LS,Zhang P,Glickman MS,Nathan CF,Geissmann F,Abel L,Franco JL, Bustamante J,Casanova JL,Boisson-Dupuis S

Year
2024

Species
Human

View more IV references on thermofisher.cn

Miscellaneous PubMed (42)

iScience

Targeting histone methylation to reprogram the transcriptional state that drives survival of drug-tolerant myeloid leukemia persisters.

"200-03 was used in Cell Culture to reveal plasticity of anthracycline resistance in AML cells and highlight the potential of transcriptional reprogramming by epigenetic-based therapeutics to target chemotherapy-resistant AML cells."

Authors: van Gils N,Verhagen HJMP,Broux M,Martiáñez T,Denkers F,Vermue E,Rutten A,Csikós T,Demeyer S,Çil M,Al M,Cools J,Janssen JJWM,Ossenkoppele GJ,Menezes RX,Smit L

Year
2022

Species
Human

View more Misc references on thermofisher.cn

More applications with references on thermofisher.cn